Latest Breaking News On - Fabian buller - Page 1 : comparemela.com

Biogen discontinues Aduhelm for Alzheimer's to focus on Leqembi

Biogen discontinues Aduhelm for Alzheimer's to focus on Leqembi
alzheimersnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzheimersnewstoday.com Daily Mail and Mail on Sunday newspapers.

Fabian bullerChristopher viehbacherPriya singhalEuropean unionDrug administration

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Fabian bullerChristoph hockChief medical officerChief business officerReverse translational medicine

Neurimmune AG: Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease

Neurimmune AG: Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan klotterChristoph hockFabian bullerChief medical officerChief business officerReverse translational medicineDie performance strategieAssets sie

Neurimmune to regain global rights to brain amyloid

Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered.

Christoph hockFabian bullerChief medical officerChief business officerReverse translational medicineNeurimmune ag

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases Zurich, Switzerland, January 17, 2022 – Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration.

Jan grimmToichi takinoMartin meier pfisterFabian bullerDiscovery research of onoOno pharmaceutical co ltdOno pharmaceuticalReverse translationalSenior executive officerExecutive director